Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 (Q24321567)

2

0 references

Kathryn Parsons

3

0 references

Carter Fields

4

0 references

Gail D Lewis Phillips

5

0 references

Lori S Friedman

6

0 references

Deepak Sampath

7

0 references

Mark X Sliwkowski

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

8

0 references

language of work or name

English

0 references

publication date

5 May 2009

0 references

published in

Cancer Cell

0 references

volume

15

0 references

page(s)

429-40

0 references

issue

5

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Cancer-specific mutations in phosphatidylinositol 3-kinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

BRAF mutation predicts sensitivity to MEK inhibition

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Exploiting the PI3K/AKT pathway for cancer drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

The selectivity of protein kinase inhibitors: a further update

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

The relationship between human epidermal growth-like factor receptor expression and cellular transformation in NIH3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Oligomers of ERBB3 have two distinct interfaces that differ in their sensitivity to disruption by heregulin.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Association with membrane protrusions makes ErbB2 an internalization-resistant receptor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

ErbB2 potentiates breast tumor proliferation through modulation of p27(Kip1)-Cdk2 complex formation: receptor overexpression does not determine growth dependency

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CCR.2009.03.020

7 January 2021